Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The objective of the study was to evaluate insulin sensitivity (Si) and disposition index (DI), all components of the MS and IGF-I and IGF binding protein (IGFBP)-3 levels in 37 previously GH-treated young SGA adults in comparison with 25 untreated short SGA controls.

Why It Was Studied

Therefore, long-term follow-up of GH-treated children born small for gestational age (SGA) is important.

Who Took Part

The age groups tagged for this paper are children, teenagers and adults, both men and women.

How the Study Was Run

The design is described as randomized and double-blind.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

The subject headings attached to it are Blood Pressure, Body Mass Index, Diabetes Mellitus, Type 2, Glucose, Growth Hormone, Infant, Small for Gestational Age and Insulin Resistance.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.